A sweeping systematic review of recent healthcare AI research reveals a critical gap: the technology is advancing faster than it can reach patients. Researchers analyzing 108 studies published between 2021 and 2026 found that the vast majority of AI healthcare systems remain trapped in laboratory or pilot settings rather than operating in routine clinical practice, according to work published in Discover Informatics.

Why Are Most Healthcare AI Tools Still in Development?

The research team, led by Deepika Yadav, Pooja Yadav, and Hemant Yadav, applied NASA's Technology Readiness Level framework to evaluate how close each AI healthcare technology actually is to real-world deployment. This nine-stage maturity scale ranges from early conceptual work to fully operational systems in widespread use.

The findings were striking: most healthcare AI technologies cluster between levels 3 and 5 on the readiness scale, meaning they exist as conceptual frameworks, proof-of-concept demonstrations, laboratory prototypes, or early tests in relevant environments. Very few studies demonstrated large-scale clinical implementation or fully operational deployment, which would correspond to the highest readiness levels.

The review began with 1,860 records drawn from major databases including PubMed, IEEE Xplore, Scopus, and ScienceDirect. After removing duplicates and screening titles and abstracts, researchers conducted full-text eligibility assessments of 331 articles before selecting 108 studies for detailed analysis.

What Types of AI Healthcare Applications Are Being Developed?

The application landscape for healthcare AI is remarkably broad. The review identified AI being deployed across multiple medical domains, including:

• Medical Imaging: Deep learning systems for radiology, pathology, dermatology, and ophthalmology that can rival or exceed human radiologist performance on malignant tumor detection
• Disease Prediction and Risk Assessment: Models that help clinicians anticipate dangers, identify lesion locations, and reduce medical errors before symptoms appear
• Automated Screening Systems: Tools accelerating diagnostics through predictive analytics and clinical decision support
• Treatment Planning: AI systems reshaping how physicians design and deliver patient care
• Fraud Detection: Blockchain-empowered analytics for identifying healthcare insurance fraud
• Remote Monitoring: Wearable devices and sensors streaming continuous patient data for real-time telehealth and remote diagnosis
• Drug Discovery: AI systems accelerating the identification of new therapeutic compounds

Deep learning, which employs artificial neural networks with millions or even billions of parameters, has proven particularly powerful in medical imaging applications. Machine learning techniques such as Support Vector Machines and Naïve Bayes classifiers are already being used to classify facial expressions for patient monitoring and disease diagnosis.

What Major Barriers Are Preventing Clinical Deployment?

The review catalogued formidable obstacles blocking the path from laboratory success to clinical reality. Data collection remains a fundamental bottleneck, as patient confidentiality concerns and privacy regulations such as GDPR limit the availability of relevant information and complicate research collaboration. Data quality problems, including inconsistent medical records, directly degrade algorithm performance.

On the algorithmic side, bias in training data can distort AI outcomes, and overfitting causes models to latch onto irrelevant correlations rather than genuine patterns. The notorious "black-box" problem, in which deep learning systems reach conclusions that even their creators cannot fully explain, undermines clinical trust and accountability. When a physician cannot understand why an AI system recommends a treatment, the reliability of medical advice itself comes into question.

Ethical and social concerns compound the technical challenges. Accountability for AI errors is difficult to assign when decision-making is opaque, and universal ethical standards for healthcare AI have yet to be established. Fear of job displacement fuels skepticism among healthcare workers, and successful adoption requires stakeholder engagement, workflow integration that does not disrupt care, and training for healthcare personnel.

How Can Healthcare Organizations Accelerate AI Deployment?

The authors chart a forward agenda for the next decade of medical AI that emphasizes practical steps for moving technology from research to reality:

• Clinical Validation: Prioritize real-world deployment and validation studies in actual clinical settings rather than controlled laboratory environments
• Explainability Focus: Develop AI models that enhance transparency and allow clinicians to understand how systems reach their recommendations
• Diverse Data Collection: Build training datasets that represent diverse patient populations to improve generalization and reduce bias
• Stakeholder Engagement: Involve physicians, nurses, patients, and administrators in the design and implementation process to ensure workflow integration
• Understudied Areas: Expand AI research into mental health, chronic disease management, and elder care, which remain relatively neglected

The review also highlights how AI is converging with other emerging technologies. The Internet of Things connects wearable devices and sensors that stream continuous patient data, enabling real-time telehealth and remote diagnosis when paired with 5G networks. Blockchain offers integrity and traceability for electronic medical records, securing data sharing across institutions through hash chains and digital signatures. Digital twin technologies create patient-specific computational models for personalized medicine, including neurosymbolic digital twins for cardiovascular disease prediction.

What Breakthrough Initiatives Are Addressing Rare Disease Diagnosis?

While most healthcare AI remains in early stages, a major new initiative is taking concrete steps to bridge the gap between research and clinical reality. UNC-Chapel Hill and Emory University are leading a first-of-its-kind research initiative to build a comprehensive data resource for diagnosing rare diseases, powered by artificial intelligence.

More than 10,000 rare diseases affect an estimated 350 million people worldwide, including as many as one in 10 Americans. Obtaining an accurate diagnosis can take years, with delays leading to inappropriate treatment, irreversible disease progression, and excessive medical costs.

"Our aim is to create a large-scale dataset spanning approximately 2,700 to train models that can then be deployed in diagnostic settings where we don't have such rich data," explained Melissa Haendel, Sarah Graham Kenan Distinguished Professor in the medical school's genetics department and faculty member at the UNC School of Data and Information Sciences.

Melissa Haendel, Sarah Graham Kenan Distinguished Professor, UNC-Chapel Hill

The 4.5-year project is supported by an up to $35 million award from the Advanced Research Projects Agency for Health, a U.S. Department of Health and Human Services agency, through the Rare Disease AI/ML for Precision Integrated Diagnostics program. The project's co-lead is Richard Moffitt, associate professor in the Emory medical school's hematology and medical oncology department.

The UNC-Chapel Hill and Emory teams will acquire data from patient registries and real-world sources, including health records, insurance claims, medical imaging, video technologies, and patient surveys. To protect patient privacy, names and identifying information will be removed before data enters the resource. Secure access will be tiered based on data sensitivity, with some datasets available publicly and others requiring data use agreements and additional safeguards.

Qualified physicians and researchers around the world will be able to apply for access to support their own research initiatives. With more data, researchers will be better positioned to reveal how rare diseases develop and progress, find patterns that can support earlier diagnosis by nonexperts, design stronger clinical trials, and accelerate drug development.

"At UNC, industry partners approach us regularly with trials on a rare disease. The challenge is that finding eligible patients can be extremely difficult. We currently have no means to find those patients. By securely bringing together more data, we hope to develop algorithms to identify trial participants more efficiently, accelerate research and expand access to clinical care," noted Haendel.

Melissa Haendel, Sarah Graham Kenan Distinguished Professor, UNC-Chapel Hill

The project team is supported by a robust public-private partnership that includes leading academic institutions, rare disease advocacy organizations, and industry partners including Johns Hopkins University, the University of California at San Francisco, and the University of Iowa. Additional program support will be provided by OpenAI, Anthropic, Amazon Web Services, and Google.

The gap between AI healthcare promise and clinical reality remains substantial, but initiatives like the rare disease data resource demonstrate that the field is beginning to address the fundamental barriers preventing deployment. As researchers prioritize clinical validation, explainability, and real-world testing, the next generation of healthcare AI tools may finally move from laboratory success to patient benefit.